ZOE Ltd
London, United Kingdom
NCT Number: NCT06800560
The MenoScale has been developed from the most common symptoms identified in over 70,000 women to reflect symptom prevalence and user-friendly terminology. It builds and improves on pre-existing scoring tools in four main ways. Firstly, the symptoms assessed are informed by prevalence, as identified from a large cohort. Secondly, the language used to ask about symptoms is modern and accessible as determined through qualitative user research. Thirdly, the impact on quality of life is assessed. Finally, it is already being offered online and completely open access.
The overall aim of this study is to validate the reliability and validity of the MenoScale as an instrument to measure menopausal symptoms and the related subjective impact on quality of life (QoL).
Looking for future studies?
Notify Me37 year–70 year
Female
Observational
London, United Kingdom
Menopause, a crucial phase in a woman's life, is the disappearance of menstruation for 12 months or longer due to depleted ovarian activity. On average, this stage accounts for over one-third of a woman's lifespan (1). In the United Kingdom (UK), the average age of menopause is 51 years, with the transitional period known as perimenopause occurring from around 45 years (2). As of 2017, there are 13 million menopausal women in the UK, with one third being aged 50 years and over in full time employment (3). It is crucial to have reliable and accessible methods for measuring and tracking symptoms in order to establish medical and lifestyle interventions which may aid in alleviating the burden of these symptoms.
All stages of menopause is accompanied by a wide variety of fluctuating symptoms and subjective experiences of women. Therefore, an online, validated questionnaire offers women the opportunity to monitor their symptoms in real- time which ultimately will: 1) raise awareness by increasing understanding around menopause; 2) empower women to track and manage their menopause themselves; and 3) facilitate conversations by providing data-backed insights to enhance discussions with healthcare providers.
The study has four main objectives:
RECRUITMENT: Potential participants will be recruited from those who are enrolled onto the ZOE Health Study as well as their friends and family. Potential participants will be contacted via email and provided with a Participant Information Sheet. Participants will be given a minimum of 24 hours after receiving the information sheet to decide whether they would like to take part in the study. Those that would like to take part in the study will be screened using an online form via a secure survey platform and eligible participants will then be asked to provide informed consent.
STUDY DESIGN: Once informed consent has been provided all participants will be asked to complete online versions of a demographics questionnaire (ethnicity, education level, menopause history [age symptoms started, age of last period], HRT usage [type and time period taken]), the MenoScale, Green Climacteric Scale, and the Short Form-36. Participants will also be asked to completed a food frequency questionnaire at baseline only. Participants will be contacted seven days later to repeat the same procedures - except for the demographics, health questionnaire and FFQ. Completion of all questionnaires is expected to take approximately 1 hour at baseline and 15 minutes at follow up.
Biological samples will not be collected in this study, nor will previously collected data be analysed.
The only primary data collection to occur during this study is the following:
References:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Female (sex assigned at birth) Aged 37 - 70 years Peri- or postmenopausal (self-reported)
Exclusion criteria
Currently pregnant and/or lactating History of hysterectomy or oophorectomy History of treatment-induced menopause Body mass index of < 18.5 Subject is taking > 5 prescribed medications Subject is unable to provide informed consent online Subject is unable understand the participant information sheet Subject is unable to complete the questionnaires online
Menopause symptom questionnaire
Menopause symptom questionnaire
Quality of life questionnaire
Other names: Short Form 36, SF36, SF-36
Food frequency questionnaire
Other names: Food frequency questionnaire, FFQ
Time frame: Baseline
The ability of the MenoScale to measure the prevalence of menopause-related symptoms in comparison to the most widely-used scale in clinical practice.
Time frame: Baseline
Time frame: Baseline and 1 week later
The reliability of the MenoScale to be repeated and how this compares to the Green Climacteric Scale
Time frame: Baseline
Associations between healthy dietary patterns, food groups and menopausal symptoms
Zoe Global Limited
Other
Validating a Novel Instrument Developed by ZOE Ltd. to Measure Menopause-related Symptoms and Quality of Life
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07695051
Hot Flashes, Menopause
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07589335
African Americans, Community Health Workers
Atlanta, Georgia, United States
View Trial DetailsNCT07651566
Menopause, Pathologic Processes
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT02618148
Menopause
Ho Chi Minh City, Vietnam
View Trial Details